Nutriband CEO issues year-end letter highlighting 2025 achievements

Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan published a letter to shareholders detailing company developments in 2025 and outlook for 2026.

The company agreed to sell 90% of its Pocono subsidiary to EarthVision Bio for $5 million, retaining a 10% stake in the new entity. Nutriband will maintain its interest if the entity lists on a major U.S. exchange.

In July, Nutriband issued a 25% preferred stock dividend to shareholders of record on July 25, 2025, with distribution occurring August 5. Each preferred share converts to one common share following FDA approval of the company's AVERSA Fentanyl product. Unconverted preferred shares receive annual cash dividends from company profits as determined by the board.

The company's warrants from its 2021 initial public offering expire October 1, 2026. Sheridan indicated these warrants may contribute to stock volatility.

For its lead product AVERSA Fentanyl, described as an abuse-deterrent opioid transdermal patch, Nutriband received patent allowances in February and June. The U.S. Patent and Trademark Office issued patent number 12,318,492 on June 3, 2025, titled "Abuse and Misuse Deterrent Transdermal Systems."

The company completed commercial manufacturing process scale-up for AVERSA Fentanyl in June and received a Type C Meeting with the FDA in August to discuss chemistry, manufacturing and controls plans.

Nutriband was added to four Russell indexes in July: Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth as part of the 2025 reconstitution.

The company scheduled its annual shareholder meeting for January 24, 2026. Information was provided in a press release statement.

You May Also Be Interested In

• MUFG Bank and JCB sign ASEAN strategic alliance MOU
• Alarum Technologies responds to FBI investigation of subsidiary NetNut
• FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk